Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in HIV-Infected Women
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01394133|
Recruitment Status : Withdrawn (Lack of enrollment)
First Posted : July 14, 2011
Last Update Posted : April 30, 2013
|Condition or disease||Intervention/treatment|
|HIV Infected||Drug: Tenofovir, Emtricitabine, Atazanavir, Ritonavir|
|Study Type :||Observational|
|Actual Enrollment :||0 participants|
|Official Title:||Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in HIV-Infected Women|
|Study Start Date :||July 2011|
|Actual Primary Completion Date :||April 2013|
|Actual Study Completion Date :||April 2013|
HIV infected women between 21-40 years of age, not receiving oral contraceptives.
Drug: Tenofovir, Emtricitabine, Atazanavir, Ritonavir
Women will be receiving Tenofovir 300mg, Emtricitabine 200mg, Atazanavir 300mg, Ritonavir 100mg, one dose on 2 separate visits. These medications will not be prescribed from the physician and not provided by the study.
- PK parameters [ Time Frame: 28 days ]The area under the concentration time curve and minimum concentration for tenofovir, emtricitabine, atazanavir and ritonavir
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01394133
|United States, Alabama|
|University of Alabama at Birmingham|
|Birmingham, Alabama, United States, 35294|